Added to YB: 2026-01-06
Pitch date: 2026-01-03
KLRS [bullish]
Kalaris Therapeutics, Inc.
-2.02%
current return
Author Info
JNap is Head of Research for Remsen Investors LP, a long/short biopharma fund and owner of Bio5C, an independent biopharma research service. Sign up for the newsletter.
Company Info
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
Market Cap
$155.2M
Pitch Price
$8.43
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-2.40
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Six Lottos For 2026 - Kalaris Therapeutics, Inc.
KLRS (lotto play): Anti-VEGF fusion protein TH103 for nAMD uses VEGFR1 domains for 10x tighter VEGF binding vs VEGFR2, potentially extending dosing to q20w-q24w vs Vabysmo's q16w. Co-founder Dr. Ferrara invented Avastin/Lucentis. $200M MCap targets $15B market; $50M raise at $10/sh, trading $8.15. Phase 1b/2 readout late 2026.
Read full article (2 min)